Jefferies Financial Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jefferies Financial Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,000	Closed	-$241K	–	1860
2026 Q1	$241K	Buy	+5,000	New	+$221K	﹤0.01%	1452
2025 Q1	–	Sell	-112,400	Closed	-$2.22M	–	1828
2024 Q4	$2.22M	Buy	112,400 +31,800	+39%	+$726K	0.01%	631
2024 Q3	$2.01M	Buy	+80,600	New	+$1.96M	0.01%	596

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Jefferies Financial Group's KNSA Position: Q2 2026 in Review

Jefferies Financial Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 5,000 shares — an estimated $241K sold.

Jefferies Financial Group first reported a position in KNSA in Q3 2024 and held it in 3 quarters. The position peaked at $2.22M in Q4 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Jefferies Financial Group reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jefferies Financial Group sold 5,000 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $241K.
Jefferies Financial Group first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 3 quarters.
Jefferies Financial Group's Kiniksa Pharmaceuticals position peaked at $2.22M in Q4 2024.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.